MOVYMIA sol inj 250 mcg/ml cartouche 2.4 ml

7680668180011 CH-66818 H05AA02 07.99.0.

Active substances:

MOVYMIA sol inj 250 mcg/ml cartouche 2.4 ml
MOVYMIA sol inj 250 mcg/ml cartouche 2.4 ml
MOVYMIA sol inj 250 mcg/ml cartouche 2.4 ml
1 / 3
google

Details

Product number
6681801
CPT
-
Packaging group
1
Unit
Stück
Composition
teriparatidum ADNr 250 µg, acidum aceticum glaciale, natrii acetas trihydricus, mannitolum, metacresolum, acidum hydrochloridum ad pH, natrii hydroxidum ad pH, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 0.03 mg.

Articles (1)

Movymia 250 μg/mL, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
04/09/2026
Professional SmPC
Français
04/09/2026
Professional SmPC
Italien
04/09/2026
Patient information leaflet
Allemand
27/08/2026
Patient information leaflet
Français
27/08/2026
Patient information leaflet
Italien
27/08/2026

Detailed composition

Substance Quantity Type Category
teriparatidum ADNr
250.0 UG Substance Wirkstoff (Principe actif)
acidum aceticum glaciale
- Substance HNIDK
natrii acetas trihydricus
- Substance HNIDK
mannitolum
- Substance HNIDK
metacresolum
- Substance Konservierungsstoff (Conservateur)
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.03 MG Substance HBESI

Reimbursement information

Public price
CHF 278.40
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/09/2019

Authorization holder

Spirig HealthCare AG

4622 Egerkingen

Authorization information

Swissmedic authorization number
66818
Drug name
Movymia, Injektionslösung
Galenic form
LSINJ
ATC Code
H05AA02
Authorization status
Z
Dispensation category
B
First authorization
17/10/2018
Authorization expiration date
31/12/9999
IT number
07.99.0.
Domain
Human medicine
Field of application
Postmenopausale Osteoporose bei Frauen; primäre und hypogonadale Osteoporose bei Männern. Glukokortikoid-induzierte Osteoporose bei Erwachsenen mit erhöhtem Frakturrisiko.

Packaging details

Description (FR)
MOVYMIA sol inj 250 mcg/ml cartouche 2.4 ml
Description (DE)
MOVYMIA Inj Lös 250 mcg/ml Patrone 2.4 ml
Market launch
17/10/2018
Narcotic (BTM)
No

Available generics

Teriparatid-Mepha, Injektionslösung im Fertigpen
CHF 225.60
View

Other packaging sizes

Buy us a coffee Explore the data